On June 24, 2025, Argentina’s National Administration of Drugs, Food and Medical Devices (ANMAT) officially adopted three key guidelines from the International Council for Harmonisation (ICH)—E2A, E2F, and E3—through its new regulation (ANMAT Disposition 4385/2025).

What this means:

• ICH E2A (Clinical Safety Data Management): Establishes clear definitions and standards for expedited safety reporting.
• ICH E2F (Development Safety Update Report): Standardizes the format and content for safety update reports during clinical development.
• ICH E3 (Clinical Study Report Structure): Defines the structure and content required for comprehensive clinical study reports.

By adopting these internationally recognized guidelines, ANMAT aims to:

✅ Harmonize local regulatory frameworks with high-standard global criteria.

✅ Improve the traceability, transparency, and quality of safety and final clinical reports.

✅ Provide sponsors with clear, standardized tools—ensuring reports are complete, well-organized, and easy to review.

✅ Strengthen the supervision of clinical trials carried out in Argentina.

This initiative underscores Argentina’s role as an official member of the ICH Regulator since June 2024, highlighting the nation’s commitment to aligning its pharmaceutical regulations with global standards.

Why it matters?

Aligning with ICH standards enhances the credibility of clinical research, supports patient safety, and fosters international collaboration in drug development.